Posts by Mourabit Halima

The 67th Annual Meeting of the American Society of Hematology (ASH) was held grandly in Orlando from December 6 to 9, 2025, bringing together the latest research and clinical advances…

Despite the remarkable progress achieved with single-target CAR-T therapy in the treatment of relapsed/refractory large B-cell lymphoma (R/R LBCL), a proportion of patients still experience suboptimal responses or relapse after treatment. At the 67th Annual Meeting of the American Society of Hematology (ASH), a study led by Professor Wang Liang from Beijing Tongren Hospital, Capital Medical University, was selected for an oral presentation, reporting impressive results from a phase II clinical trial of dual-target CD19/CD22 CAR-T cell therapy in R/R LBCL. The findings attracted wide attention. Hematology Frontier invited Professor Wang Liang for an in-depth discussion of the innovative aspects of this study, offering valuable insights for future optimization of R/R LBCL treatment strategies and research directions.

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was grandly held in Orlando, USA. As the world’s largest and most influential international academic conference in the field of hematology, the ASH Annual Meeting attracts tens of thousands of experts and scholars each year to share the latest advances and breakthrough research. At this year’s meeting, a study led by Professor Sun Ruijuan from Lu Daopei Hospital was selected for poster presentation, focusing on the clinical efficacy of allogeneic hematopoietic stem cell transplantation in infant acute leukemia, providing important insights for the treatment of this challenging patient population. Hematology Frontier invited Professor Sun to share the details of this study for academic exchange.

The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9, 2025, showcasing the latest global advances in hematology. Multiple studies…

At the 67th Annual Meeting of the American Society of Hematology (ASH), Prof. Ou Bai and her team from The First Hospital of Jilin University presented multiple impactful studies. Two…

In recent years, with the rapid development of precision genomics, hereditary predisposition genes have gained increasing attention for their clinical value in the diagnosis and treatment of hematologic malignancies. At the 67th Annual Meeting of the American Society of Hematology (ASH), a study led by Professor Li Zhihui from Beijing Gaobo Boren Hospital was selected for oral presentation, systematically evaluating the impact of hereditary predisposition genes on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and donor selection. Hematology Frontier invited Professor Li for an in-depth interpretation of this study and its implications for clinical practice.

At this year’s American Society of Hematology (ASH) Annual Meeting, advances in FLT3-ITD acute myeloid leukemia (AML) delivered important clinical insights. From evolving treatment paradigms to optimized maintenance strategies and breakthroughs in targeted therapy, these studies consistently centered on precision medicine, driving care toward greater efficiency and individualization. On site at ASH, Hematology Frontier invited Professor Jun Ma from the Harbin Institute of Hematology and Oncology to interpret key developments in dynamic management, maintenance therapy, and targeted drug application in FLT3-ITD AML, with the aim of informing clinical decision-making.